887330-11-2

Upstream product

• 75-77-4 chloro-trimethyl-silane 
• 84983-97-1 N-benzylidene-L-valinol 

Downstream Products

• 844470-77-5 (S)-2-[((S)-1-cyclopropyl-1-phenyl-methyl)-amino]-3-methyl-butan-1-ol 

Relevant academic research and scientific papers

COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE

The present invention relates to compounds of formula (I), a pharmaceutically acceptable salt or solvate thereof: wherein n, m and p, which may be the same or different, are either 0 or 1. Also disclosed are processes for their preparation, pharmaceutical compositions containing them and their use as medicaments particularly in treating disorders of the central nervous system (CNS).

COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE

The invention also relates to compounds of formula (I), a pharmaceutically acceptable salt, solvate or prodrug thereof: wherein R1 is phenyl or cyclohexyl, either of which is optionally substituted by 1, 2 or 3 halogen atoms, which atoms may be the same or different; R2 is C1-6alkyl or C3-6cycloalkyl; n is 1 or 2; R3 is hydrogen, C1-6alkyl or C3-6cycloalkyl; X is -(C=O)- or -SO2-; R4 is C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6haloalkoxy, amino, monoC1-6alkylamino or diC1-6alkylamino, or R4 is heterocyclyl or carbocyclyl, either of which is optionally substituted independently by one or more halogen, C1-6alkyl, C1-6haloalkyl, C1-6alkoxy or C1-6haloalkoxy; R5 is phenyl or thienyl, either of which is optionally substituted by 1, 2 or 3 halogen atoms; and y is 0, 1 or 2; wherein when y is 1 or 2, Y is a halogen atom, and wherein when y is 2 the halogen atoms may be the same or different. Also disclosed are use of the compounds in treating diseases and conditions mediated by activation of the NK3 receptor, compositions containing the derivatives and processes for their preparation.

COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE

The present invention relates to compounds of formula (I), a pharmaceutically acceptable salt, solvate or prodrug thereof: wherein R1 is phenyl optionally substituted by 1, 2 or 3 halogen atoms which halogen atoms may be the same or different; R2 is C1-6alkyl, C3-6cycloalkyl or acetyl; X is oxygen or sulphur; a is 1, 2 or 3; b is 0 or 1; c is 0, 1 or 2; R3 is hydrogen or C1-6alkyl; R4 is hydrogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxyC1-6alkyl, C3-6cycloalkyl or C3-6cycloalkylC1-6alkyl; R5 is hydrogen; or R5 and R3, together with the nterconnecting atoms, form a 4, 5 or 6 membered ring; R6 is phenyl or thienyl, either of which is optionally substituted by 1, 2 or 3 halogen atoms, which atoms may be the same or different; and z is 0, 1 or 2; wherein when z is 1 or 2, Z is a halogen atom, and wherein when z is 2 the halogen atoms may be the same or different. Also disclosed are processes for their preparation, pharmaceutical compositions containing them and heir use as medicaments particularly in treating disorders of the Central Nervous System (CNS).

QUINOLINE 4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS NEUROKININ 3 (NK-3) RECEPTOR ANTAGONISTS

The invention relates to novel quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments particularly in treating disorders of the central nervous system (CNS).